Haemonetics Corporation (HAE)

Debt-to-equity ratio

		Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Long-term debt	US$ in thousands	797,564	754,102	559,441	690,592	305,513
Total stockholders’ equity	US$ in thousands	959,959	817,997	749,424	731,670	587,109
Debt-to-equity ratio		0.83	0.92	0.75	0.94	0.52

March 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $797,564K ÷ $959,959K
= 0.83

The debt-to-equity ratio of Haemonetics Corporation has shown varying trends over the past five years. In the most recent fiscal year ending March 31, 2024, the ratio decreased to 0.83 from 0.92 in the previous year, indicating a lower level of debt relative to equity. This suggests that the company has reduced its reliance on debt financing compared to the prior year.

Looking further back, the trend highlights fluctuations in the debt-to-equity ratio: it was 0.75 in 2022, increased to 0.94 in 2021, and was relatively lower at 0.52 in 2020. These fluctuations suggest that Haemonetics has actively managed its capital structure, periodically adjusting its debt and equity mix to optimize its financial leverage.

Overall, the decreasing trend in the debt-to-equity ratio over the past two years may indicate a concerted effort by Haemonetics to strengthen its capital structure by reducing debt levels or increasing equity investments. This trend could potentially lead to improved financial stability and lower financial risk for the company in the long term.